P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS

P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS

Bibliographic Details
Main Authors:	I. Johnson, K. McCullough, F. Farrukh, A. Al-Kali, H. Alkhateeb, K. Begna, A. Mangaonkar, M. Litzow, W. Hogan, M. Shah, M. Patnaik, A. Pardanani, A. Tefferi, N. Gangat
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845064.44923.05

Similar Items

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
by: Maansi Joshi, et al.
Published: (2021-03-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
by: Rimal Ilyas, et al.
Published: (2023-02-01)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
by: Naseema Gangat, et al.
Published: (2023-01-01)

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
by: K. H. Begna, et al.
Published: (2022-01-01)

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”
by: K. H. Begna, et al.
Published: (2022-04-01)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
by: Mithun Vinod Shah, et al.
Published: (2022-07-01)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
by: Naseema Gangat, et al.
Published: (2020-11-01)

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-04-01)

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
by: Ayalew Tefferi, et al.
Published: (2024-03-01)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
by: Ahmad Ghorab, et al.
Published: (2022-06-01)

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
by: Talha Badar, et al.
Published: (2024-02-01)

The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study
by: Liu Q, et al.
Published: (2021-01-01)

P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
by: A. Baranwal, et al.
Published: (2022-06-01)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
by: Mostafa Abdallah, et al.
Published: (2023-03-01)

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
by: Maymona G. Abdelmagid, et al.
Published: (2022-07-01)

P572: VENETOCLAX AND HYPOMETHYLATING AGENT COMBINATIONS FOR THE TREATMENT OF ADVANCED MYELOPROLIFERATIVE NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY DISEASE
by: K. Sanber, et al.
Published: (2022-06-01)

Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance
by: Rahul Mishra, et al.
Published: (2023-12-01)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Rami Basmaci, et al.
Published: (2023-08-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience
by: Ahmad Nanaa, et al.
Published: (2021-06-01)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
by: Rami S. Komrokji, et al.
Published: (2022-11-01)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
by: Kebede H. Begna, et al.
Published: (2021-03-01)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Bahga Katamesh, et al.
Published: (2023-08-01)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
by: Aref Al-Kali, et al.
Published: (2023-04-01)

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
by: Talha Badar, et al.
Published: (2023-09-01)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Muhamad Oum, et al.
Published: (2023-08-01)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
by: Ayalew Tefferi, et al.
Published: (2023-07-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
by: Gianluca Martini, et al.
Published: (2023-08-01)

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
by: Aleksina Shatilova, et al.
Published: (2021-05-01)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Amrutha Sai Mittapalli, et al.
Published: (2023-08-01)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
by: Minerva Montalvo Saavedra, et al.
Published: (2023-08-01)

One thousand patients with essential thrombocythemia: the Mayo Clinic experience
by: Naseema Gangat, et al.
Published: (2024-01-01)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
by: Fangli Chen, et al.
Published: (2023-08-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
by: Zhangjie Chen, et al.
Published: (2023-03-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
by: Xuezhu Xu, et al.
Published: (2023-12-01)

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
by: Byungho Lim, et al.
Published: (2022-04-01)

Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis
by: Fanghua Ye, et al.
Published: (2023-09-01)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
by: Xiaoyan Hu, et al.
Published: (2023-02-01)